
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
2nd Annual Burning Issues in Psychiatry (BIPSYCH) Conference
October 12-14, 2012 (tbc); Dubai, United Arab Emirates




